0000950170-23-032913.txt : 20230713 0000950170-23-032913.hdr.sgml : 20230713 20230713212614 ACCESSION NUMBER: 0000950170-23-032913 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230711 FILED AS OF DATE: 20230713 DATE AS OF CHANGE: 20230713 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: NSV Partners III GP LLC CENTRAL INDEX KEY: 0001889601 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40928 FILM NUMBER: 231087872 BUSINESS ADDRESS: STREET 1: 500 WEST PUTNAM AVE STREET 2: SUITE 400 CITY: GREENWICH STATE: CT ZIP: 06830 BUSINESS PHONE: 2126885100 MAIL ADDRESS: STREET 1: 500 WEST PUTNAM AVE STREET 2: SUITE 400 CITY: GREENWICH STATE: CT ZIP: 06830 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: NSV Partners III LP CENTRAL INDEX KEY: 0001890004 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40928 FILM NUMBER: 231087873 BUSINESS ADDRESS: STREET 1: 500 WEST PUTNAM AVE STREET 2: SUITE 400 CITY: GREENWICH STATE: CT ZIP: 06830 BUSINESS PHONE: 2126885100 MAIL ADDRESS: STREET 1: 500 WEST PUTNAM AVE STREET 2: SUITE 400 CITY: GREENWICH STATE: CT ZIP: 06830 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ventyx Biosciences, Inc. CENTRAL INDEX KEY: 0001851194 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 832996852 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 662 ENCINITAS BLVD., STE. 250 CITY: ENCINITAS STATE: CA ZIP: 92024 BUSINESS PHONE: (858) 945-2393 MAIL ADDRESS: STREET 1: 662 ENCINITAS BLVD., STE. 250 CITY: ENCINITAS STATE: CA ZIP: 92024 4 1 ownership.xml 4 X0407 4 2023-07-11 0001851194 Ventyx Biosciences, Inc. VTYX 0001890004 NSV Partners III LP 500 WEST PUTNAM AVENUE, SUITE 400 GREENWICH CT 06830 false false true false 0001889601 NSV Partners III GP LLC 500 WEST PUTNAM AVENUE, SUITE 400 GREENWICH CT 06830 false false true false false Common Stock 2023-07-11 4 S false 28646 37.5414 D 8560141 D Common Stock 2023-07-12 4 S false 3275 37.6242 D 8556866 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by NSV Partners III, L.P. on February 24, 2023. Represents the weighted average share price of an aggregate total of 28,646 shares sold in the price range of $37.50 to $37.675. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. NSV Partners III, L.P. is the general partner of NSV Investments I, L.P., NSV Investments III, L.P., and NSV Investments II, L.P. Somasundaram Subramaniam is the majority member and managing member of NSV Partners III GP, LLC, and may be deemed to have voting and dispositive power over the shares owned by each entity of which NSV Partners III, L.P. is general partner. Mr. Subramaniam is the majority member and managing member NSV Partners II, LLC. Mr. Subramaniam is the majority member and managing member of New Science Ventures, LLC. Mr. Subramaniam disclaims beneficial ownership over the shares owned by each of the NSV Funds (as defined below), except to the extent of his pecuniary interest therein. Mr. Subramaniam is a director of the issuer and files separate reports under Section 16 of the Securities Exchange Act of 1934, as amended. The shares beneficially owned by the reporting persons consist of: (i) 5,004,701 shares held by NSV Investments I, L.P., (ii) 978,835 shares held by NSV Investments III, L.P., (iii) 1,502,112 shares held by NSV Partners III, L.P., (iv) 434,423 shares held by New Science Ventures, LLC, (v) 408,520 shares held by NSV Partners II, LLC, and (vi) 232,180 shares held by NSV Investments II, L.P. (collectively, the "NSV Funds"). The NSV Funds disclaim beneficial ownership over the shares owned by them, except to the extent of their pecuniary interest therein. Represents the weighted average share price of an aggregate total of 3,275 shares sold in the price range of $37.50 to $37.862. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. The shares beneficially owned by the reporting persons consist of: (i) 5,004,701 shares held by NSV Investments I, L.P., (ii) 978,835 shares held by NSV Investments III, L.P., (iii) 1,498,837 shares held by NSV Partners III, L.P., (iv) 434,423 shares held by New Science Ventures, LLC, (v) 408,520 shares held by NSV Partners II, LLC, and (vi) 232,180 shares held by NSV Investments II, L.P. The NSV Funds disclaim beneficial ownership over the shares owned by them, except to the extent of their pecuniary interest therein. /s/ NSV Partners III, LP, By: Brenda Marex, Chief Financial Officer 2023-07-13 /s/ NSV Partners III GP, LLC, By: Brenda Marex, Chief Financial Officer 2023-07-13